Myofibrillar Ca2+ sensitivity is uncoupled from troponin i phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin T

Cardiovascular Research

Volumn 97, Issue 3, 2013, Pages 500-508

  Bayliss, Christopher R ^a   Jacques, Adam M ^a   Leung, Man Ching ^a   Ward, Douglas G ^b   Redwood, Charles S ^c   Gallon, Clare E ^d   Copeland, O'Neal ^a   McKenna, William J ^e   Dos Remedios, Cristobal ^f   Marston, Steven B ^a   Messer, Andrew E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiac muscle contractility; Hypertrophic cardiomyopathy; Phosphorylation; Troponin I; Troponin T

Indexed keywords

CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; SERINE; TROPONIN I; TROPONIN T;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INFRARED SPECTROSCOPY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUSCLE RESECTION; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING;

ADULT; BIOPSY; CALCIUM; CARDIOMYOPATHY, HYPERTROPHIC; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYOCARDIUM; MYOFIBRILS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TROPONIN I; TROPONIN T;

EID: 84874257414     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs322     Document Type: Article

References (49)

1. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. New Eng J Med 2011;364:1643-1656.
2. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C et al. Hypertrophic cardiomyopathy distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-2232.
3. Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation 2003;108:445-451.
4. Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:602-610.
5. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:1903-1910.
6. Marston SB. How do mutations in contractile proteins cause the primary familial cardiomyopathies? J Cardiovasc Transl Res 2011;4:245-255.
7. Hoskins AC, Jacques A, Bardswell SC, McKenna WJ, Tsang V, Remedios C et al. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. J Mol Cell Cardiol 2010;49:737-745.
8. Jacques A, Briceno N, Messer A, Gallon C, Jalizadeh S, Garcia E et al. The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. Cardiovasc Res 2008;79:481-491.
9. Jacques A, Hoskins A, Kentish J, Marston SB. From genotype to phenotype: a longitudinal study of a patient with hypertrophic cardiomyopathy due to a mutation in the MYBPC3 gene. J Musc Res Cell Motil 2009;29:239-246.
10. Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L, Warshaw DM. R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Musc Res Cell Motil 2000;21:609-620.
11. Van Dijk S, Dooijes D, Dos Remedios C, Michels M, Lamers J, Winegrad S et al. Cardiac myosin-binding protein c mutations and hypertrophic cardiomyopathy. Haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009;119:1473-1483.
12. Song W, Dyer E, Stuckey D, Copeland O, Leung M, Bayliss C et al. Molecular mechanism of the Glu99lys mutation in cardiac actin (ACTC gene) that causes apical hypertrophy in man and mouse. J Biol Chem 2011;286:27582-27593.
13. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-567.
14. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999;44:20-36.
15. Tardiff JC. Thin filament mutations: developing an integrative approach to a complex disorder. Circ Res 2011;108:765-782.
16. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975;52:88-102.
17. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-1624.
18. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-1941.
19. Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 2009;105:219-222.
20. Jacques A, Copeland O, Messer A, Gallon C, King C, McKenna W et al. Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle. J Mol Cell Cardiol 2008;45:209-216.
21. Copeland O, Nowak K, Laing N, Ravenscroft G, Messer AE, Bayliss CR et al. Investigation of changes in skeletal muscle alpha-actin expression in normal and pathological human and mouse hearts. J Musc Res Cell Motil 2010;31:207-214.
22. Copeland O, Sadayappan S, Messer AE, Stienen GJ, Velden J, Marston SB. Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. J Mol Cell Cardiol 2010;49:1003-1011.
23. Messer A, Gallon C, McKenna W, Elliott P, Dos Remedios C, Marston S. The use of phosphate-affinity SDS-PAGE to measure the troponin I phosphorylation site distribution in human heart muscle. Proteomics Clin Appl 2009;3:1371-1382.
24. Dyer E, Jacques A, Hoskins A, Ward D, Gallon C, Messer A et al. Functional analysis of a unique troponin C mutation, Gly159Asp that causes familial dilated cardiomyopathy, studied in explanted heart muscle. Circ Heart Fail 2009;2:456-464.
25. Messer AE, Jacques AM, Marston SB. Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol 2007; 42:247-259.
26. Jacques A, Messer A, Tsang V, McKenna W, Marston S. Evidence for reduced troponin I phosphorylation and altered troponin function in patients with hypertrophic obstructive cardiomyopathy. Heart 2006;92(Supp II):A29.
27. Kron SJ, Toyoshima YY, Uyeda TQP, Spudich JA. Assays for actin sliding movement over myosin coated surfaces. Methods Enzymol 1991;196:399-416.
28. Fraser IDC, Marston SB. In Vitro motility analysis of actin-tropomyosin regulation by troponin and Ca2+: the thin filament is switched as a single cooperative unit. J Biol Chem 1995;270:7836-7841.
29. Marston SB, Fraser IDC, Wu B, Roper G. A simple method for automatic tracking of actin filaments in the motility assay. J Musc Res Cell Motil 1996;17:497-506.
30. Song W, Dyer E, Stuckey D, Leung M-C, Memo M, Mansfield C et al. Investigation of a transgenic mouse model of familial dilated cardiomyopathy. J Mol Cell Cardiol 2010; 49:380-389.
31. Leung M-C, Messer AE, Copeland On, Marston SB. O-Glcnacylation in the long isoform of ZASP in human heart muscle. Biophys J 2012;102:143a.
32. Bing W, Fraser IDC, Marston SB. Troponin I and troponin T interact with troponin C to produce different Ca2+-dependant effects on actin-tropomyosin filament motility. Biochem J 1997;327:335-340.
33. Potter JD, Sheng Z, Pan B, Zhao J. A direct regulatory role for troponin T and a dual role for troponin C in the Ca2+ regulation of muscle contraction. J Biol Chem 1995; 270:2557-2562.
34. Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans. A comparison among normal and failing heart, fetal heart and adult and fetal skeletal muscle. Circ Res 1991;69:1226-1233.
35. Marston S, Redwood CS. Modulation of thin filament activation by breakdown or isoform switching of thin filament proteins physiological and pathological implications. Circ Res 2003;93:1170-1178.
36. Sancho Solis R, Ge Y, Walker JW. Single amino acid sequence polymorphisms in rat cardiac troponin revealed by top-down tandem mass spectrometry. J Muscle Res Cell Motil 2009;29:203-212.
37. Bayliss C. Dysfunction of Contractile Proteins in Hypertrophic Cardiomyopathy. PhD Thesis. Imperial College London: 2012:1-341.
38. Memo M, Messer AE, Marston SB. Mutations in thin filament proteins that cause familial dilated cardiomyopathy uncouple troponin I phosphorylation from changes in myofibrillar Ca2+ sensitivity. Circulation 2011;124:A13162.
39. Biesiadecki BJ, Kobayashi T, Walker JS, John Solaro R, de Tombe PP. The troponin C G159D mutation blunts myofilament desensitization induced by troponin I Ser23/24 phosphorylation. Circ Res 2007;100:1486-1493.
40. Deng Y, Schmidtmann A, Kruse S, Filatov V, Heilmeyer LM Jr, Jaquet K et al. Phosphorylation of human cardiac troponin I G203S and K206Q linked to familial hypertrophic cardiomyopathy affects actomyosin interaction in different ways. J Mol Cell Cardiol 2003;35:1365-1374.
41. Knott A, Purcell IF, Marston S. In vitro motility analysis of thin filaments from failing and non-failing human hearts induces slower filament sliding and higher Ca2+-sensitivity. J Mol Cell Cardiol 2002;34:469-482.
42. Zhang J, Zhang H, Ayaz-Guner S, Chen Y-C, Dong X, Xu Q et al. Phosphorylation, but not alternative splicing or proteolytic degradation, is conserved in human and mouse cardiac troponin T. Biochemistry 2011;50:6081-6092.
43. Jin JP, Huang QQ, Yeh HI, Lin JJ. Complete nucleotide sequence and structural organization of rat cardiac troponin T gene. A single gene generates embryonic and adult isoforms via developmentally regulated alternative splicing. J Mol Biol 1992; 227:1269-1276.
44. Memo M, Messer AE, Leung M-C, Marston SB. Mutations in thin filament proteins that cause familial dilated cardiomyopathy uncouple troponin I phosphorylation from changes in myofibrillar Ca2+ sensitivity. Biophys J 2012;102:614a.
45. Solaro RJ, Rosevear P, Kobayashi T. The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun 2008;369:82-87.
46. Howarth JW, Meller J, Solaro RJ, Trewhella J, Rosevear PR. Phosphorylationdependent conformational transition of the cardiac specific N-extension of troponin I in cardiac troponin. J Mol Biol 2007;373:706-722.
47. Huke S, Knollmann BC. Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. J Mol Cell Cardiol 2010;48:824-833.
48. Yasuda S, Coutu P, Sadayappan S, Robbins J, Metzger JM. Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res 2007;101:377-386.
49. Chen PP, Patel JR, Rybakova IN,Walker JW, Moss RL. Protein kinase A-induced myofilament desensitization to Ca(2+) as a result of phosphorylation of cardiac myosinbinding protein C. J Gen Physiol 2010;136:615-627.